2Eric L Eisenstein, DBA,Kevin J. Anstrom, PhD,David F. Kong, MD,Linda K. Shaw, MS,Robert H. Tuttle, MSPH,Daniel B. Mark, MD, MPH,Judith M. Kramer, MD, MS,Robert A. Harrington, MD,David B. Matchar, MD,David E. Kandzari, MD 1,Eric D. Peterson, MD, MPH,Kevin A. Schulman, MD,Robert M. Califf, MD,李呈亿（译）,David E. Kandzari, MD.氯吡格雷的使用与药物洗脱支架植入后远期临床结果[J].美国医学会杂志（中文版）,2007,26(3):131-139. 被引量：59
1Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost,2000; 84:891 - 896.
2Jarvis Blair, Simpson Kerryn. Clopidogrel : A Review of its Use in the Prevention of Atherothrombosis. Drugs, 60(2) : 347-377.
3Kearney AS, Crawford LF, Mehta SC, et al. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxuacid forms of the HMG - CoA reductase inhibitor, CI - 981.Pharm Res, 1993; 10:1461 - 1465.
4Lea AP, McTavish D. Atorvastatin : a review of its pharmacology and therapeutic potential in the management of hyperlipidemias.Drugs, 1997;53:828 - 847.
5Thummel KE,Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol, 1998; 38: 389 - 430.
6Tannous M, Cheung R, Vignini A, et al. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects.Thromb Haemost, 1999; 82 (5) : 1390 - 1394.
7Viigimaa M, Valkman R. Lipid - lowering and anti - aggregatory efficacy of atorvastatin in coronary heart disease patients with combined hyperlipidemia. Atherosclerosis 1999 May 24; 144 Suppl.1:24.
8Hebert PR, Gaziano JM, Chan KS, et al.Cholesterol loweing with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA, 1997;278:1660 - 1661.
9Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardic events following successful first percutaneous coronary intervention: a randomized controlled trial .IAMA, 2002;287: 3215-3 222.
10Serebruany VL, Malinin AI, Kallahan KP, et al. Statins do not affect platelet inhibition with clopidogrel during coronary stenting.Atherosclerosis, 2001; 239:259 - 261.
